FONDAZIONE PER L’ISTITUTO ONCOLOGICO DI RICERCA (Switzerland)
HOPITAUX UNIVERSITAIRES DE GENEVE (Switzerland)
Inventor
Alimonti, Andrea
Migliorini, Denis
Abstract
The present invention concerns dual-targeting of PSMA and a novel senescence marker, Nectin2, on prostate cancer cells by immunoresponsive cell therapy that uses dual-targeting CAR immunoresponsive cells, or dual-targeting CAR/synthetic Notch (synNotch) receptor immunoresponsive cells recognizing PSMA and Nectin2. The invention further concerns related nucleic acids, vectors, CARs, CAR/synNotch receptors, and immunoresponsive cells.
FONDAZIONE PER L'ISTITUTO ONCOLOGICO DI RICERCA (Switzerland)
UNIVERSITE DE GENEVE (Switzerland)
HOPITAUX UNIVERSITAIRES DE GENEVE (Switzerland)
Inventor
Alimonti, Andrea
Migliorini, Denis
Kohl, Anna
Bressan, Silvia
Abstract
The present invention concerns anti-Nectin2 antibodies, or antigen binding fragment thereof, anti-PSMA antibodies, or antigen binding fragment thereof, bispecific antibody constructs that bind to Nectin2 and PSMA, and antibody-drug conjugates comprising such antibodies. The invention further relates to the antibody-drug conjugates for use for the treatment of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
4.
DEVICE AND METHOD FOR MEASURING PARAMETERS OF A PATIENT
The present relates to a device for measuring at least one parameter of a patient, the device comprising a casing equipped with at least one sensor for measuring said parameter of the patient. The device comprises at least three sensors, each sensor being configured for measuring one distinct parameter, said three sensors being chosen among a list comprising at least a temperature sensor to measure a temperature of the patient, a sound sensor to record a body sound of the patient and an oximeter sensor to measure a blood oxygen level of the patient. The three sensors are mounted in the casing so that when the device is in contact with the skin of the patient, at least two distinct parameters, preferably three distinct parameters, are measured simultaneously.
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
The present relates to a method for detecting a disease in a patient comprising providing chest recordings of the patient, processing the chest recordings with a computational tool, detecting the presence or the absence of said disease depending on the output of the computational tool, the chests recordings are recorded from a plurality of distinct acquisition sites distributed on the patient's chests, the processing of the chest recordings comprises i) applying a first computation tool on the chest recordings of each of acquisition site to compute a first score for each recording of each of acquisition site; ii) aggregating all the first scores computed for the patient by applying a second computational tool to compute a global score for the patient for said disease; iii) determining the presence or the absence of the disease based on the global score.
The invention provides an isolated peptide and a peptide construct of formula I that binds antiphospholipid antibodies (aPLA). The present invention further provides methods for detection of aPLA. The present invention also provides methods for diagnosing and treating the antiphospholipid syndrome (APS).
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
7.
Pharmaceutical Composition For Allergen Specific Immunotherapy
The invention relates to intradermal administration of an allergen for desensitization and/or tolerance induction of allergic patients and for treatment and prophylaxis of allergy. More specifically, it relates to the administration of an allergen and a local vasoconstrictor through the intradermal route to enable a slow release of allergen and lower side effects of therapy.
The present relates to a device for measuring at least one parameter of a patient, the device comprising a casing equipped with at least one sensor for measuring said parameter of the patient. The device comprises at least three sensors, each sensor being configured for measuring one distinct parameter, said three sensors being chosen among a list comprising at least a temperature sensor to measure a temperature of the patient, a sound sensor to record a body sound of the patient and an oximeter sensor to measure a blood oxygen level of the patient. The three sensors are mounted in the casing so that when the device is in contact with the skin of the patient, at least two distinct parameters, preferably three distinct parameters, are measured simultaneously.
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
9.
PEPTIDES AND USE THEREOF FOR DIAGNOSING AND TREATING ANTIPHOSPHOLIPID SYNDROME
The invention provides an isolated peptide and a peptide construct of formula I that binds antiphospholipid antibodies (aPLA). The present invention further provides methods for detection of aPLA. The present invention also provides methods for diagnosing and treating the antiphospholipid syndrome (APS).
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61P 37/00 - Drugs for immunological or allergic disorders
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
10.
PHARMACEUTICAL COMPOSITION FOR ALLERGEN SPECIFIC IMMUNOTHERAPY
The invention relates to intradermal administration of an allergen for desensitization and/or tolerance induction of allergic patients and for treatment and prophylaxis of allergy. More specifically, it relates to the administration of an allergen and a local vasoconstrictor through the intradermal route to enable a slow release of allergen and lower side effects of therapy.
The present relates to a positioning and shaping shell manufacturing method for manufacturing a positioning and shaping shell comprising a positioning step consisting in positioning and supporting a target body portion with a transparent body shaper in a predetermined position on a positioning board presenting at least one transparent portion permitting scanning through it, an image acquisition step consisting in a target body portion surface scan imaging also via the transparent portion of the board and said transparent body support, a software computing step where the acquired image data are sent and processed in a processing unit, and a producing step consisting in producing a 3D positioning and shaping shell model via additive or subtractive manufacturing method based in the processed image data.
The present relates to a positioning and shaping shell manufacturing method for manufacturing a positioning and shaping shell comprising a positioning step consisting in positioning and supporting a target body portion with a transparent body shaper in a predetermined position on a positioning board presenting at least one transparent portion permitting scanning through it, an image acquisition step consisting in a target body portion surface scan imaging also via the transparent portion of the board and said transparent body support, a software computing step where the acquired image data are sent and processed in a processing unit, and a producing step consisting in producing a 3D positioning and shaping shell model via additive or subtractive manufacturing method based in the processed image data.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
16.
BARD1 isoforms in lung and colorectal cancer and use thereof
The present invention relates to new BARD1 isoforms specific to lung cancer and colorectal cancer, a method for detecting thereof and a method for treating and/or preventing lung cancer and colorectal cancer.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
17.
SYSTEM AND METHOD FOR CHECKING THE WASHING OF HANDS
A method for checking the washing of hands, comprising the following steps: the tilting and the duration of said tilting of a soap container (2) is detected by means of a first inertial sensor (204); data (d1) dependent on said tilting and said duration are transmitted wirelessly; a bracelet (1) displays an indication (10-12) dependent on said data and representative of hand hygiene.
G08B 21/24 - Reminder alarms, e.g. anti-loss alarms
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
G09B 19/00 - Teaching not covered by other main groups of this subclass
18.
METHOD AND DEVICE FOR VERIFYING WHETHER HANDS HAVE BEEN WASHED
Method for detecting, by means of an inertial sensor, whether hands have been disinfected or washed, comprising: a first detection of a hand position allowing liquid soap to be received, followed by: a second detection of a rubbing movement by means of said inertial sensor (14); confirmation is given that hands have been disinfected or washed in the case where the first detection is followed by the second detection.
The present invention relates to new BARD1 isoforms specific to lung cancer and colorectal cancer, a method for detecting thereof and a method for treating and/or preventing lung cancer and colorectal cancer.
In accordance with an aspect of the invention, an apparatus for the treatment and/or prevention of corneal diseases is provided, the apparatus comprising - an applicator head, the applicator head comprising a radiation source capable of exciting a non-toxic chromophore; and - a control operable to activate the radiation source to radiate; wherein at least one of the following two conditions is met: - the applicator head comprises a sensor capable of measuring a signal dependent on a position of the applicator head relative to the cornea; - the applicator head is configured to be in physical contact with the cornea; and wherein the control is operable to activate the radiation source to radiate depending on a signal measured by the sensor or to activate the radiation source when the applicator head touches the cornea, respectively.
+ epitope. It also relates to antigen presenting cells loaded with said polypeptides, and the use thereof in immunotherapy including prevention and/or treatment of cancers or infectious diseases.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 9/86 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase
A61K 39/00 - Medicinal preparations containing antigens or antibodies
22.
BARD1 ISOFORMS IN LUNG AND COLORECTAL CANCER AND USE THEREOF
The present invention relates to new BARDl iso forms specific to lung cancer and colorectal cancer, a method for detecting thereof and a method for treating and/or preventing lung cancer and colorectal cancer.
The present invention relates to new BARDl iso forms specific to lung cancer and colorectal cancer, a method for detecting thereof and a method for treating and/or preventing lung cancer and colorectal cancer.
The present invention relates to the compounds useful in the prevention and/or treatment of tumours. More specifically the present invention relates to inhibitors of the activity of the electron transport chains and/or the mitochondrial TCA cycle in glioma-initiating cells (GICs) for use in a method for preventing and/or treating tumours presenting glioma-initiating cells (GICs) in a subject who has undergone a prior removal of a tumour glioma bulk. The present invention further provides a pharmaceutical composition containing the inhibitors of the invention and a screening method for identifying the inhibitors of the invention.
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The present invention is related to methods for the preparation of cell compositions, isolated compositions obtainable therefrom, related isolated cell compositions, kits and use thereof. More specifically, the present invention provides a method for identifying, purifying and enriching immature or stem cancer-initiating cells in a 5 sample. The cell compositions, related methods and uses according to the present invention are useful in the treatment of cancers and/or the detection of enriching immature or stem cancer-initiating cells, notably cancers of the central and peripheral nervous system, metastasis to the brain.
The present invention relates to an inhibitor of a protein, wherein said protein (i) comprises or consists of the amino acid sequence of SEQ ID NOs: 2 or 4, or is encoded by a nucleic acid comprising or consisting of the sequence of SEQ ID NOs: 1 or 3; (ii) comprises or consists of the amino acid sequence of SEQ ID NO: 26, or is encoded by a nucleic acid comprising or consisting of the sequence of SEQ ID NO: 25; (iii) is a fragment of the protein according to (i), or has a sequence at least 75% identical with the protein according to (i) or with said fragment of the protein according to (i), and exhibits NADPH oxidase activity; or (iv) is a fragment of the protein according to (ii) or has a sequence at least 75% identical with the protein according to (ii) or with said fragment of the protein according to (ii) and stabilizes said protein exhibiting NADPH oxidase activity; and/or an inhibitor of a nucleic acid, wherein said nucleic (v) comprises or consists of the nucleic acid sequence of SEQ ID NO: 1 or 3, or encodes a protein comprising or consisting of the sequence of SEQ ID NO: 2 or 4; (vi) comprises or consists of the nucleic acid sequence of SEQ ID NO: 25, or encodes a protein comprising or consisting of the sequence of SEQ ID NO: 26; (vii) is a fragment of the nucleic acid according to (v), or has a sequence at least 75% identical with the nucleic acid according to (v) or with said fragment of the nucleic acid according to (v), and encodes a protein exhibiting NADPH oxidase activity; or (viii) is a fragment of the nucleic acid according to (vi), or has a sequence at least 75% identical with the nucleic acid according to (vi) or with said fragment of the nucleic acid according to (vi), and encodes a protein stabilizing said protein exhibiting NADPH oxidase activity; for treatment and/or prevention of cataract and/or presbyopia. The sequences define NADPH oxidases or a subunit of an NADPH oxidase, respectively. A preferred inhibitor is a siRNA. Also provided are a method of treating cataract and presbyopia, pharmaceutical compositions, medical uses and diagnostic uses of compounds of the invention.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia
The present invention relates to new protein isoforms, use thereof, methods of preparation thereof, methods of detection thereof, antibodies thereof, combination of antibodies thereof,use of these antibodies and combination thereof and use of antagonists of those isoforms for the treatment of gynaecological cancers.
The present invention provides methods to determine if a patient has or is at risk for developing a renal disorder. In certain embodiments, specific biomarkers are provided which may be used to determine if a patient has or is at risk for developing a renal disorder (e.g., acute renal failure).
A system and method is disclosed which detects a specific cognitive-emotional mental state (e.g., passion) in a subject. The system and method utilizes different Internal Personalized Explorer (IPE) stimuli subliminally exposed to the subject on a visual display. Following exposure, the subject performs a target-specific cognitive task and a related behavior (e.g., deciding whether a briefly displayed string of letters is a word or not, and pressing a button to indicate the decision). The decision reaction time for the behavior is recorded in a computer database. The reaction times are interpreted quantitatively to detect the relative intensity of the specific cognitive-emotional mental state in the subject. A reaction time for a specific individual IPE that is shorter than the mean reaction time for an IPE that does not evoke the emotional state indicates that the specific individual IPE did evoke the emotional state in the subject.
The present invention relates to methods and compositions for the detection and treatment of melanoma and skin cancers. More particularly, the invention discloses that BCSC-1 expression is altered in melanoma and skin cancer cells, allowing the design of effective detection methods and kits for such conditions. The invention also shows that restoring or increasing expression of BCSC-1 in melanoma and skin cancer cells suppresses tumorigenicity and represents a novel and effective approach for the treatment of melanoma and skin cancers. The invention may be used to detect the presence, stage or type of melanoma and skin cancers, as well as any predisposition thereto. The invention may be used in any mammalian subject, particularly human subjects.
ECOLE POLYTECHNIQUE FEDERAL DE LAUSANNE (EPFL) (Switzerland)
HOPITAUX UNIVERSITAIRES DE GENEVE (Switzerland)
Inventor
Rüfenacht, Daniel
Doelker, Eric
Jordan, Olivier
Chastellain, Mathiew
Petri-Fink, Alke
Hofmann, Heinrich
Abstract
The injectable formulation for treatment by hyperthermia comprises a liquid carrier and heat-generating superparamagnetic iron oxide nanoparticles having a mean diameter not greater than 20 nm. Said injectable formulation is able to form in-situ a hyperthermic solid or semi-solid implant upon contact with a body fluid or tissue. Said hyperthermic solid or semi-solid implant may be useful for treating a tumor or a degenerative disc disease by hyperthermia.
patents
